Search

Your search keyword '"Canesi, M."' showing total 6 results
Start Over Author "Canesi, M." Journal parkinsonism & related disorders
6 results on '"Canesi, M."'

2. 1.111 CLINICAL AND NEUROPSYCHOLOGICAL CHARACTERIZATION OF PATIENTS WITH PARKINSON'S DISEASE AND DOPAMINE DYSREGULATION SYNDROME

Author

Cilia, R., primary, Siri, C., additional, Canesi, M., additional, De Gaspari, D., additional, Zecchinelli, A.L., additional, Meucci, N., additional, Zini, M., additional, Ruffmann, C., additional, Isaias, I.U., additional, Mariani, C.B., additional, Tesei, S., additional, Sacilotto, G., additional, and Pezzoli, G., additional

Published
2012
Full Text
View/download PDF

3. 2.262 Adherence to antiparkinson medication in a multi-centre European study.

Author

Grosset, D., primary, Antonini, A., additional, Canesi, M., additional, Pezzoli, G., additional, Lees, A., additional, Shaw, K., additional, Cubo, E., additional, Martinez-Martin, P., additional, Rascol, O., additional, Negres-Pages, L., additional, Senard, A., additional, Schwarz, J., additional, Strecker, K., additional, Reichmann, H., additional, Storch, A., additional, Loehle, M., additional, and Stocchi, F., additional

Published
2007
Full Text
View/download PDF

6. Predictors of COVID-19 outcome in Parkinsons disease

Author

Araceli Alonso-Canovas, Carlo Dallocchio, Gianni Pezzoli, Antonio E. Elia, Alfonso Fasano, Chiara Sorbera, Dario Alimonti, Margherita Canesi, Fasano, A, Elia, A, Dallocchio, C, Canesi, M, Alimonti, D, Sorbera, C, Alonso-Canovas, A, and Pezzoli, G

Subjects
Male, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Time Factors, Parkinson's disease, Deep brain stimulation, Deep Brain Stimulation, medicine.medical_treatment, Clinical Neurology, Comorbidity, Disease, Iran, Severity of Illness Index, Article, Antiparkinson Agents, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Severity of illness, medicine, Humans, Dementia, Aged, Outcome, Aged, 80 and over, business.industry, COVID-19, Parkinson Disease, Middle Aged, medicine.disease, Obesity, United Kingdom, Hospitalization, 030104 developmental biology, Italy, Neurology, Spain, Hypertension, Cohort, Female, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Abstract

Introduction Specific pre-existing medical conditions (e.g. hypertension or obesity), advanced age and male sex appear linked to more severe manifestations of SARS Co-V2 infection, thus raising the question of whether Parkinson's disease (PD) poses an increased risk of morbidity and mortality in COVID-19 patients. Methods In order to describe the outcome of COVID-19 in multi-centre a cohort of PD patients and explore its potential predictors, we gathered the clinical information of 117 community-dwelling patients with COVID-19 followed in 21 tertiary centres in Italy, Iran, Spain, and the UK. Results Overall mortality was 19.7%, with a significant effect of co-occurrence of dementia, hypertension, and PD duration. Conclusions The frailty caused by advanced PD poses an increased risk of mortality during COVID-19., Highlights • Specific pre-existing conditions are linked to worse COVID-19 outcome. • Whether Parkinson's disease (PD) poses an increased risk is unknown. • 117 PD patients with COVID-19 from in 21 centres in 4 country were analyzed. • Mortality was 19.7%, with an effect of dementia, hypertension, and PD duration. • The frailty caused by advanced PD increased the risk of mortality during COVID-19.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results